Print This Page

Important Safety Information Full Prescribing Information


Perception vs Reality

CINV is a Problem

Predicted and observed nausea and vomiting incidence rates following MEC1*

* In a prospective, observational study of 14 medical oncology practices, medical oncologists and oncology nurses estimated incidence of acute and delayed CINV after first administration of HEC and MEC in their own practices.

† Patients in the practices completed a 6-day diary, including emetic episodes, nausea assessment, and antiemetic use.

  • Actual rate of delayed CINV was shown to be approximately twice that estimated by healthcare practitioners1

Prevention of CINV is the Goal2

Patients with poor control of nausea and vomiting during prior chemotherapy cycles are likely to experience nausea and vomiting in subsequent cycles.3

Indication

In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

  • Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
  • Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

References
  1. Grunberg S., et al. Incidence of Chemotherapy-Induced Nausea and Emesis after Modern Antiemetics: Perception versus Reality, Cancer. 2004;100(number 10):2261-2268.
  2. Referenced and adapted with permission from The NCCN Clinical Practice Guidelines in Oncology™ Antiemesis V.1.2010. © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  3. National Cancer Institute. General risk factors and etiologies. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page 4. Accessed March 31, 2010.
Sitemap | Legal Notice and Disclaimers | Privacy

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed and marketed by Eisai Inc.
© 2010 Eisai Inc.
All rights reserved. AL562B 7/10